Replace (6:21 AM ET): Article up to date with newest share motion
Insulet (NASDAQ:PODD) shares have been in deal with Friday after the medical gadget firm agency reported preliminary outcomes for the second quarter of 2024.
Q2 income of $488M was up 23% Y/Y and additionally exceeded the estimated progress of 15% to 18% in fixed foreign money, due to income outperformance for all product traces. The highest-line efficiency additionally surpassed Wall Road estimates of $460.51M.
“Second quarter income exceeded our expectations throughout the board on account of sturdy demand for Omnipod 5, leading to sturdy income progress and sequential will increase in new buyer begins in each the U.S. and worldwide markets,” mentioned Jim Hollingshead, president and chief government officer.
Omnipod income, the corporate’s tubeless insulin pump expertise, grew 26% to $480M, with drug supply income coming at $8M.
The corporate expects to boost its full 12 months Omnipod income outlook to a variety of 18% to 21% (vs. 15% to 19% earlier) when it releases its full monetary outcomes on August 8, 2024.
Shares had fallen round 6% in preliminary response to the information, however gained round 4% shortly after
